Frontiers in Molecular Biosciences

metrics 2024

Shaping the Future of Health through Molecular Insights

Introduction

Frontiers in Molecular Biosciences is an esteemed open-access journal published by FRONTIERS MEDIA SA, based in Switzerland. Since its inception in 2014, the journal has made significant strides in the fields of biochemistry, genetics, and molecular biology, cementing its reputation with a solid position in the Q1 quartile for both Biochemistry and Genetics and Molecular Biology (miscellaneous) categories as of 2023. With a remarkable Scopus rank of #14/103 in the combined categories, it offers an essential platform for the dissemination of high-quality research that shapes the understanding of molecular processes and their implications in health and disease. The journal’s commitment to open access facilitates the broadest possible reach for groundbreaking discoveries, serving as a vital resource for researchers, professionals, and students alike. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, this journal continues to foster innovative discussions and advancements in molecular biosciences, paving the way for new insights and collaborations in the scientific community.

Metrics 2024

SCIMAGO Journal Rank-
Journal Impact Factor3.90
Journal Impact Factor (5 years)4.40
H-Index-
Journal IF Without Self3.90
Eigen Factor0.03
Normal Eigen Factor6.55
Influence1.08
Immediacy Index0.80
Cited Half Life2.50
Citing Half Life7.00
JCI0.70
Total Documents-
WOS Total Citations16153
SCIMAGO Total Citations-
SCIMAGO SELF Citations-
Scopus Journal Rank-
Cites / Document (2 Years)-
Cites / Document (3 Years)-
Cites / Document (4 Years)-

Metrics History

Rank 2024

IF (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 104/313
Percentile 66.90
Quartile Q2

JCI (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 141/313
Percentile 54.95
Quartile Q2

Quartile History

Similar Journals

CURRENT DRUG TARGETS

Exploring Innovative Therapeutic Strategies
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

EXPERIMENTAL AND MOLECULAR MEDICINE

Connecting scholars to the latest in experimental medicine.
Publisher: SPRINGERNATUREISSN: 1226-3613Frequency: 12 issues/year

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.

Genes & Diseases

Unlocking the secrets of genes to combat diseases.
Publisher: KEAI PUBLISHING LTDISSN: 2352-4820Frequency: 6 issues/year

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Unveiling Critical Perspectives in Biochemistry
Publisher: TAYLOR & FRANCIS LTDISSN: 1040-9238Frequency: 6 issues/year

Welcome to Critical Reviews in Biochemistry and Molecular Biology, a premier academic journal published by Taylor & Francis Ltd, dedicated to advancing the fields of biochemistry and molecular biology. With an impressive impact factor and a Q1 ranking in both Biochemistry and Molecular Biology for 2023, this journal serves as a vital resource for researchers, professionals, and students eager to engage with cutting-edge reviews and analyses that synthesize the latest developments in these dynamic areas of study. Since its inception in 1972, the journal has maintained a commitment to high-quality scholarship, providing a platform for critical discussions that accelerate the discovery and understanding of biochemical processes and molecular interactions. Although not open access, its robust editorial peer-review process ensures that published articles meet the highest standards of scientific rigor, making it a trusted source for the scientific community. As we continue to converge toward 2024, we invite you to explore the extensive array of topics and findings that have shaped contemporary biochemistry and molecular biology.

CURRENT MOLECULAR MEDICINE

Exploring the Molecular Mechanisms of Health and Disease
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5240Frequency: 10 issues/year

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

CELLULAR SIGNALLING

Transforming Understanding of Cellular Dynamics
Publisher: ELSEVIER SCIENCE INCISSN: 0898-6568Frequency: 12 issues/year

CELLULAR SIGNALLING, published by Elsevier Science Inc, is a premier journal within the realm of Cell Biology, boasting an impressive Q2 category ranking as of 2023. With an ISSN of 0898-6568 and an E-ISSN of 1873-3913, the journal has established itself as a critical platform for advancing the understanding of cellular mechanisms and signal transduction pathways since its inception in 1989. Covering a vast array of topics in Biochemistry, Genetics, and Molecular Biology, it ranks notably at 87 out of 285 in the Scopus list, placing it in the 69th percentile among its peers. The journal serves as an invaluable resource for researchers, professionals, and students seeking high-quality, impactful studies that drive forward the field of cellular biology. While it operates under traditional subscription access, its highlights include rigorous peer-reviewed articles, reviews, and insights that continue to shape current scientific discourse.

BIOCHEMICAL JOURNAL

Advancing the Frontiers of Biochemical Research
Publisher: PORTLAND PRESS LTDISSN: 0264-6021Frequency: 24 issues/year

BIOCHEMICAL JOURNAL, published by Portland Press Ltd, stands as a leading publication in the fields of Biochemistry, Cell Biology, and Molecular Biology, reflecting a commitment to advancing scientific knowledge since its inception in 1945. With a distinguished Q1 ranking across these categories and impressive Scopus rankings, the journal serves as an invaluable resource for researchers, professionals, and students alike, facilitating critical discoveries and innovative research practices. Although not currently offering open access, the journal provides a platform for high-quality peer-reviewed articles, ensuring rigorous standards in the dissemination of biochemical research. Spanning over seven decades and continuing through to 2024, the BIOCHEMICAL JOURNAL fosters an environment where cutting-edge biochemical research thrives, supporting the global scientific community's efforts to address complex biological questions and enhance our understanding of fundamental cellular processes.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Elevating Knowledge in Biochemistry and Biophysics
Publisher: ELSEVIERISSN: 0304-4165Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, published by Elsevier, serves as a pivotal journal in the fields of biochemistry and biophysics, with a long-standing history dating back to 1956. This esteemed publication, bearing the ISSN 0304-4165 and E-ISSN 1872-8006, continuously contributes to advancing our understanding of complex biological processes through rigorous research articles and reviews. It notably holds a distinguished position with a Q2 classification in Biochemistry and a Q1 ranking in Biophysics for 2023, reflecting its high relevance and impact within these scientific domains. The journal is also recognized within the Scopus metrics, taking a rank of #40 out of 152 in Biophysics and #173 out of 438 in Biochemistry, thus placing it in the 74th and 60th percentiles respectively. Academics and professionals in the life sciences will find this journal an essential resource for current research, cutting-edge techniques, and comprehensive reviews aimed at enhancing the understanding of biological functions. While BIOCHIMICA ET BIOPHYSICA ACTA is not an open-access journal, it remains a cornerstone publication for those seeking to stay at the forefront of biochemical and biophysical research.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Bridging Molecular Biology and Clinical Insights
Publisher: ELSEVIERISSN: 0925-4439Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

Biology Direct

Elevating your understanding of biology.
Publisher: BMCISSN: Frequency: 1 issue/year

Biology Direct is a leading open-access journal published by BMC, dedicated to disseminating groundbreaking research in the fields of biological sciences. Since its inception in 2006, the journal has emerged as a pivotal platform for scholars, researchers, and practitioners, providing unrestricted access to high-quality, peer-reviewed articles that cover a wide spectrum of topics, including biochemistry, ecology, and applied mathematics. With an impressive ranking in the first quartile across multiple scientific categories, including Agricultural and Biological Sciences and Biochemistry, Genetics, and Molecular Biology, Biology Direct is recognized for its rigorous standards and impactful contributions within the academic community. The journal's open-access model ensures that research findings reach a global audience, fostering collaboration and innovation. Researchers and students looking to stay ahead in the rapidly evolving biological sciences will find Biology Direct an invaluable resource for knowledge and insight.